Pay in 4 interest-free payments of $5.82 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
19,20 Retatrutide, a triple GLP-1/GIP/glucagon agonist, has demonstrated the greatest reported efficacy to date, with weight loss reaching approximately 24.2% in adult clinical trials
Once your order has been received and processed, we will forward the tracking information to the email linked to your patient portal
In a 12-week trial involving individuals with a BMI of 2743 kg/m, the highest-dose group achieved an 11.3% average weight reduction, a top-tier result for early-stage trials
Then move to your thighs or arms the following month
The thigh offers a larger, more accessible injection area than the abdomen for many patients, making it an ideal choice for weekly GLP-1 therapy
Cancer, diabetes, and brain issues are examples
US$ 21.68
US$ 29.78
US$ 27.54
US$ 26.44
US$ 22.20
US$ 26.17
